Zai Lab Ltd (ZLAB) stock
ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30471% above fair value
$24.60−1.44 (-5.53%)
Close on Nov 13, 2026Market cap $3.82BP/E –Yield –
Zai Lab r&d expenses
Research and development expenses are spending on new products and technology.
Zai Lab's R&D Expenses for the twelve months ending Sep 30, 2026 was $238.80M, up 12.9% year over year. For fiscal 2025 it was $220.90M, down 5.8% from the year before. Over ten years it grew 32.2% a year on average. The highest annual figure on record is $573.31M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.90M | -5.8% |
| FY2024 | Dec 31, 2024 | $234.50M | -11.8% |
| FY2023 | Dec 31, 2023 | $265.87M | -7.2% |
| FY2022 | Dec 31, 2022 | $286.41M | -50.0% |
| FY2021 | Dec 31, 2021 | $573.31M | +157.4% |
| FY2020 | Dec 31, 2020 | $222.71M | +56.6% |
| FY2019 | Dec 31, 2019 | $142.22M | +18.2% |
| FY2018 | Dec 31, 2018 | $120.28M | +205.7% |
| FY2017 | Dec 31, 2017 | $39.34M | +22.4% |
| FY2016 | Dec 31, 2016 | $32.15M | +136.6% |
| FY2015 | Dec 31, 2015 | $13.59M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $49.81M | +3.9% |
| Q2 FY2026 | Jun 30, 2026 | $61.77M | +22.0% |
| Q1 FY2026 | Mar 31, 2026 | $65.59M | +8.0% |
| Q4 FY2025 | Dec 31, 2025 | $61.63M | +18.0% |
| Q3 FY2025 | Sep 30, 2025 | $47.93M | -27.4% |
| Q2 FY2025 | Jun 30, 2025 | $50.61M | -17.9% |
| Q1 FY2025 | Mar 31, 2025 | $60.73M | +11.1% |
| Q4 FY2024 | Dec 31, 2024 | $52.25M | -36.2% |
| Q3 FY2024 | Sep 30, 2024 | $65.98M | +12.3% |
| Q2 FY2024 | Jun 30, 2024 | $61.63M | -19.6% |
| Q1 FY2024 | Mar 31, 2024 | $54.65M | +12.7% |
| Q4 FY2023 | Dec 31, 2023 | $81.95M | +22.4% |
| Q3 FY2023 | Sep 30, 2023 | $58.77M | -41.0% |
| Q2 FY2023 | Jun 30, 2023 | $76.68M | +16.0% |
| Q1 FY2023 | Mar 31, 2023 | $48.47M | -10.0% |
| Q4 FY2022 | Dec 31, 2022 | $66.95M | -61.1% |
| Q3 FY2022 | Sep 30, 2022 | $99.52M | +80.5% |
| Q2 FY2022 | Jun 30, 2022 | $66.08M | -53.5% |
| Q1 FY2022 | Mar 31, 2022 | $53.85M | -73.6% |
| Q4 FY2021 | Dec 31, 2021 | $172.09M | +175.1% |
| Q3 FY2021 | Sep 30, 2021 | $55.14M | -5.1% |
| Q2 FY2021 | Jun 30, 2021 | $142.22M | +108.2% |
| Q1 FY2021 | Mar 31, 2021 | $203.85M | +504.1% |
| Q4 FY2020 | Dec 31, 2020 | $62.56M | +94.9% |
| Q3 FY2020 | Sep 30, 2020 | $58.10M | +13.5% |
| Q2 FY2020 | Jun 30, 2020 | $68.31M | +22.7% |
| Q1 FY2020 | Mar 31, 2020 | $33.74M | – |
| Q4 FY2019 | Dec 31, 2019 | $32.10M | – |
| Q3 FY2019 | Sep 30, 2019 | $51.20M | – |
| Q4 FY2018 | Dec 31, 2018 | $55.65M | – |
See a number that looks wrong?